Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand,
BioDrugs. 2013 Feb;27(1):75-81. doi: 10.1007/s40259-012-0009-y.
Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis vaccine (Tdap; Boostrix(®)) is indicated for booster vaccination against diphtheria, tetanus, and pertussis. In clinical trials, a single booster dose of Tdap induced high seroprotective levels of antibodies to its three component acellular pertussis antigens in virtually all children and adolescents, and in a high proportion of adults and elderly individuals, at ≈1 month post-vaccination, irrespective of their vaccination history. Seropositivity rates for antibodies against pertussis toxin had begun to decline by 5 years after a booster dose of Tdap in adolescents/adults, with a subsequent booster dose 10 years later generally as immunogenic and as well tolerated as the initial booster. Tdap was safe and well tolerated in all age groups.
减少抗原、联合白喉、破伤风和无细胞百日咳组份疫苗（Tdap；Boostrix(®)）被批准用于加强免疫接种，以预防白喉、破伤风和百日咳。在临床试验中，Tdap 的单剂加强免疫在 ≈1 个月后，几乎所有儿童和青少年以及很大比例的成人和老年人中，均可诱导针对其三种无细胞百日咳组份抗原的高血清保护性抗体水平，而与他们的疫苗接种史无关。在青少年/成人接种 Tdap 加强针 5 年后，针对百日咳毒素的抗体阳性率开始下降，而随后在 10 年后再次加强免疫，其免疫原性和耐受性与初始加强免疫一样好。Tdap 在所有年龄组中均安全且耐受良好。
